Pfizer: Another Settlement Down
This article goes through the case, the settlement, and what it means for the future. Our readers may remember the “agreement in principle” reached between Pfizer, Inc. and the Department of Justice (“DOJ”) to settle the qui tam case with Wyeth, LLC. That agreement was recently made official by the parties, with the settlement being signed, sealed, and delivered on April 27, 2016. As a refresher, allegations were made by Lauren Kieff, a former hospital sales representative for AstraZeneca Pharmaceuticals LP, and William St. John LaCorte, a physician, that Wyeth engaged in healthcare fraud from 2001 to 2006. These allegations covered two Proton Pump Inhibitors (PPIs), both commonly used to treat acid reflux disease, Protonix Oral, and Protonix I.V. Shortly after coming to market, Protonix I.V. was not selling as well as Wyeth had hoped. Allegedly, Wyeth sought to induce hospitals to buy and use the drugs in such a manner that when patients were discharged from the hospital on Protonix Oral, they were more likely to stay on the medication for extended periods of time, instead of switching to competing PPIs. After being discharged from the hospital, payers (including Medicaid) would pay almost full price for the drugs. Read Full Article in the July 2016 Issue of Life Science Compliance Update To Read the Full Story, Subscribe, Download a Sample Issue, or Sign In
Authors: Yin CY, Zhang SS, Zhong JT, Zhou SH Abstract Laryngeal and hypopharyngeal carcinomas are common malignant tumors of the head and neck, which are both exhibiting increasing incidences. Laryngopharyngeal reflux is the retrograde flow of gastric contents into the larynx, oropharynx, and/or nasopharynx. There remains controversy regarding whether laryngopharyngeal reflux is a risk factor for laryngeal and hypopharyngeal cancers. The refluxing substances mainly include hydrochloric acid, pepsin, and occasionally bile acids and bile salts, as well as bacteria that colonize the gastrointestinal tract. Loss of epi...
ConclusionOverall, bariatric surgery (SG or RYGB) remains a low mortality risk procedure for all age groups. However, all age group classifications > 45 years had higher incidence of major complications and mortality compared to patients 18–45 years (despite older individuals having lower preoperative BMI) indicating delaying surgery is detrimental.
Cystic fibrosis is a multisystem disorder, and gastrointestinal disease contributes significantly to its morbidity. This review outlines the major gastrointestinal manifestations of CF, and highlights areas of common misunderstanding. Areas particularly important to practice, such as impact upon malabsorption, bowel obstruction and gastro-oesophageal reflux are considered in detail.
Although many studies in China have found that environmental or lifestyle factors are major contributors to the etiology of esophageal cancer, most of the patients in the above studies are in the middle and late stages, the early-stage patients account for a small proportion. To clarify the risk/protective factors contributing to early lesions, we conducted the present cross-sectional study. A total of 2925 healthy controls and 402 patients with esophageal precancerous lesions were included in our study by endoscopic examination. Information on risk/protective factors was collected by personal interview, and unconditional...
Morbidly obese patients often suffer from gastroesophageal reflux disease (GERD). High-resolution impedance manometry (HRIM) allows a comprehensive evaluation of esophageal motility and esophagogastric junction (EGJ) morphology and helps to clarify GERD pathophysiology.
AbstractBackgroundAlthough a third of gastroesophageal reflux disease (GERD) patients are refractory to proton pump inhibitor (PPI) therapy, the underlying mechanism of the refractoriness remains unclear. We compared the level of gastric acid suppression during PPI treatment between responders and non-responders by directly measuring gastric acid secretion in GERD patients taking PPIs.MethodsSeventy-five consecutive patients receiving standard-dose PPI therapy for GERD were prospectively recruited, irrespective of persistent GERD symptoms. They were asked about their GERD symptoms using a validated questionnaire, and simul...
CONCLUSION: Laparoscopic anti-reflux surgery can be performed safely as a day case procedure even in larger hiatus hernias, with a dedicated care pathway and specialist nurse practitioners to support it. PMID: 32735121 [PubMed - as supplied by publisher]
No abstract available
Conclusions: Gastric H. pylori infection, ethnicity, gender, and age all influence the occurrence of Barrett metaplasia, and reflux esophagitis.
In the article, “7RECENT Advances in Endoscopic Treatments for Gastroesophageal Reflux Disease,” published in the September issue of Current Treatment Options in Gastroenterology, the title is printed in correctly.